Grade ≥ 3 SAEs
| Adverse event . | n . | % . |
|---|---|---|
| Rash* | 4 | 11 |
| Pulmonary† | 2 | 6 |
| Arthritis‡ | 1 | 3 |
| Graft failure§ | 1 | 3 |
| LFT elevation | 1 | 3 |
| Hypertension | 1 | 3 |
| Hypotension | 1 | 3 |
| Acute kidney injury | 1 | 3 |
| Adverse event . | n . | % . |
|---|---|---|
| Rash* | 4 | 11 |
| Pulmonary† | 2 | 6 |
| Arthritis‡ | 1 | 3 |
| Graft failure§ | 1 | 3 |
| LFT elevation | 1 | 3 |
| Hypertension | 1 | 3 |
| Hypotension | 1 | 3 |
| Acute kidney injury | 1 | 3 |
SAEs include any Common Terminology Criteria of Adverse Events 4.0 while being treated with pegIFNα, irrespective of attribution. Nine patients (25%) experienced a total of the 12 SAEs listed above.
LFT, liver function tests (aspartate transaminase/alanine transaminase).
Clinical features consistent with acute GVHD.
Pulmonary SAEs include pneumonitis (acute respiratory distress syndrome) related to infection (n = 1) and acute hypoxemia (n = 1).
Clinical features consistent with gouty arthritis.
Met criteria for DLT.